Business Context and Reporting Period
This Form 8-K Current Report was filed by Syndax Pharmaceuticals, Inc. on June 8, 2022, regarding events occurring on June 13, 2022. The filing discloses the appointment of a new Chief Financial Officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
- Annual Base Salary: $450,000
- Annual Target Bonus: 40% of base salary
- Sign-on Bonus (RSU): $50,000 fair value, vesting over two years
- Stock Option Grant: 230,000 shares, exercisable at the closing price on June 13, 2022
Material Changes
The primary material change is the appointment of Keith A. Goldan as Chief Financial Officer, Principal Financial Officer, and Treasurer, effective June 13, 2022. He replaces Alexander Nolte, who served as interim Principal Financial Officer, though Nolte remains Principal Accounting Officer.
Outlook, Risks, and Unusual Items
Employment Terms and Severance: The Employment Agreement includes specific severance provisions:
- Termination without Cause/Good Reason: 9 months base salary, 9 months health benefits, and accelerated vesting of equity that would have vested within 12 months.
- Change in Control Proximity: If termination occurs within 3 months prior to or 12 months after a change in control, severance increases to 12 months base salary plus 100% of the target bonus, 12 months health benefits, and full accelerated vesting of all unvested options.
Risks: The filing notes that severance benefits are contingent upon Mr. Goldan signing a general release of claims.
Investor Verification Checklist
- Verify the closing stock price on June 13, 2022, to determine the exercise price of the 230,000 stock options.
- Review the full text of the Employment Agreement (Exhibit 10.1) for detailed definitions of "cause," "good reason," and "change in control."
- Confirm the vesting schedule commencement date for the stock options and RSUs.
- Assess the impact of the new CFO's background (previously CFO of OptiNose, Fibrocell Science, NuPathe, PuriCore, and Biosyn) on the company's financial strategy.